Resumen de: WO2019075344A1

The present disclosure provides methods and treatment regimens for treating an inflammatory bowel disease (IBD), e.g., ulcerative colitis (UC), in a subject in need thereof. The present disclosure further provides adjusting a dosing regimen for fecal-microbiome therapy of IBD based on a level of a fecal marker for intestinal inflammation. Further provided are methods comprising providing a therapeutic dosing regimen to a patient with a gastrointestinal disorder (e.g., IBD) in need thereof, the method comprising administering to the patient a therapeutic composition comprising fecal microbes based upon a level of a fecal marker for intestinal inflammation. An exemplary fecal marker is calprotectin. This disclosure also provides a method for screening or selecting a fecal donor by testing efficacy of the donor's fecal material in inducing desirable changes in a fecal marker for intestinal inflammation in an IBD patient (e.g., UC patient).

Resumen de: WO2019074432A1

The present invention relates to a method for determining if a subject suffers from Crohn ́s disease or from ulcerative colitis, wherein the method comprises the steps of determining if the subject suffers from inflammatory bowel disease and determining the proportion of B-cells which are CD27 + in a sample from the subject. The method may further comprise determining the proportion of CD8 + T-cells which are HLA-DR + in a sample from the subject. The present invention also relates to biomarkers for use as a marker in the diagnosis of inflammatory bowel disease, Crohn ́s disease ulcerative colitis. The present invention also relates to a kit for the diagnosis of Crohn ́s disease and/or ulcerative colitis.

Resumen de: WO2019073391A1

The disclosure provides a method for predicting that a subject having inflammatory bowel disease (IBD) will have a clinical response or remission to an anti-α4β7 integrin during the course of therapy by assessing the concentration of the anti-α4β7 integrin drug at the induction or maintenance phase, respectively in a sample from the subject. The disclosure also provides a method for predicting whether a subject having inflammatory bowel disease (IBD) will be a remitter to an anti-α4β7 integrin drug treatment regimen by detecting the presence or level of at least one predictive marker.

Resumen de: US2019094223A1

Provided are methods of predicting responsiveness of a subject having an inflammatory bowel disease (IBD) to a tumor necrosis factor (TNF)-alpha inhibitor, by analyzing a frequency of at least one subpopulation of immune cells in a tissue biopsy of the subject. Also provided are methods of selecting a treatment for a subject and kits for determining responsiveness of the subject to treatment with a TNF-alpha inhibitor.

Resumen de: WO2017201461A1

The present invention describes a method of prognosing high or low probability of developing an inflammatory bowel disease (IBD) in a subject and a method of diagnosing an inflammatory bowel disease (IBD) in a subject. The invention further provides for a method of identifying genes/genetic loci associated with a disease condition, such as IBD, CD and/or UC.

Resumen de: US2019083574A1

Thermogenic molecules and methods of using these molecules for treating or preventing a condition in a subject selected from the group consisting of visceral fat accumulation (e.g., Crohn's disease associated with visceral fat accumulation), obesity, diabetes, pre-diabetes, hypothermia, and chronic inflammation are disclosed. Also disclosed is a method for promoting glucose uptake in peripheral tissues (e.g., adipocytes and muscles) of a subject, enhancing nerve innervation in a subject, activating PI3 kinase in cell, and inducing leptin secretion by an adipocyte. Also disclosed are inhibitors of thermogenic molecules and methods of using these inhibitors to decrease thermogenesis of adipocytes in a subject. Also disclosed are self-assembled, biocompatible nanostructure non-covalently associated with a therapeutic or diagnostic peptide or peptidomimetic.

Resumen de: WO2019050899A1

The disclosure provides nucleic acid molecules, including cDNA, comprising an alteration that encodes a truncated human Single Immunoglobulin Interleukin-1 Receptor Related (SIGIRR) protein. The disclosure also provides isolated and recombinant human SIGIRR protein variants that comprise a truncation at a position corresponding to position 215. The truncation, and the nucleic acid molecules encoding this change, associate with early-onset inflammatory bowel disease (EO-IBD). The disclosure also provides methods for determining whether a subject has or has a risk of developing EO-IBD, based on the identification of such alterations in the nucleic acid molecules encoding SIGIRR.

Resumen de: KR20190021940A

본 발명은 개의 장 질환으로 인한 염증의 진단을 위해 사용될 수 있는, 신규 바이오마커 및 그 용도에 관한 것으로서, 보다 상세하게는 substance P 신규 바이오마커 및 그 용도인 바이오마커를 이용한 진단방법에 관한 것이다. 본 발명에 따르면, 전신 염증을 동반한 장 질환의 심각한 정도를 판단할 수 있는 특이적 진단 마커를 제공함으로써, 장 질환으로 인한 염증의 치료 및 예후관리에 유용한 자료를 제공한다. 또한, 상기 장 질환 특이적 염증 진단 마커는 장 질환의 염증을 조기 진단할 수 있으며, 치료제 개발연구에 이용되어 전신염증으로 인한 조직 손상 및 다발성 장기 부전을 방지할 수 있다.

Resumen de: AU2014269961A1

The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, the present invention is useful for determining whether the individual does not have either celiac disease or inflammatory bowel disease (IBD), and has IBS and/or a subtype thereof. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions.

Resumen de: US2019062414A1

The invention relates to the diagnosis and treatment of diseases,including inflammatory disorders, proliferative disorders and autoimmune diseases. The invention provides, and involves the use of, antibody molecules that bind: i) lysozyme, ii) neutrophil elastase, iii) tissue inhibitor of metalloproteinase-1 (TIMP-1), or iv) the D domain of Tenascin-C. The invention also relates to the use of antibody molecules that bind v) the IIICS isoform of fibronectin, vi) the Extra Domain-B (ED-B) of fibronectin, vii) matrix-metalloproteinase 3 (MMP3), or viii) the A1 domain of tenascin-C in the diagnosis and treatment of inflammatory disorders such as inflammatory bowel disease.

Resumen de: US2019064181A1

A method for monitoring the effectiveness of an anti-TNF-alpha-treatment, e.g. of an inflammatory bowel disease, using Interleukin-22 binding protein (IL-22BP) as a prognostic biomarker. The method comprises determining the expression level of Interleukin-22 binding protein (IL-22BP) in a biological sample obtained from a subject.

Resumen de: US2019053749A1

The present disclosure relates to methods and devices to detect perforation of the bowel, for example, resulting from surgical procedures, such as laparoscopy, diagnostic procedures, such as colonoscopy, medical conditions, such as diverticulitis, and trauma. The present disclosure also relates to filtration systems and electrical connector assemblies for use in the methods and devices.

Resumen de: AU2017293417A1

The present invention provides a method of assessing whether an individual is at high risk or low risk of inflammatory bowel disease (IBD) progression by determining the expression level of two or more genes in a whole blood sample. Also provided are methods for treating IBD in an individual who is determined to be at high risk or low risk for IBD progression, and kits for assessing whether an individual is at high risk or low risk for IBD progression. Arrays, and methods of providing arrays, of patient-identified selected gene expression products from a whole blood sample of a patient are also provided.

Resumen de: WO2019025624A1

The invention relates to the identification of biomarkers of the response status of a patient for a treatment with anti-TNFalpha agents,for treatment with anti-α4β7 agents or with both anti-TNFalpha agent and anti-α4β7agents and to their use in assessing such status, in particular for assessing nonresponsive status for a treatment with anti-TNFalpha agents or respectively with anti-α4β7 agent in human patients suffering from inflammatory condition or disease, in particular Inflammatory Bowel Disease (IBD), in particular Ulcerative Colitis or Crohn's disease. The invention describes a method of in vitro assessing whether a treatment with anti- TNFalpha agent or with anti-α4β7 agent may be useful in a human patient suffering from inflammatory condition or disease, in particular when said condition or disease is a chronic and/or relapsing one, particularly a gastrointestinal, more particularly intestinal, inflammatory condition or disease which is eligible for treatment with anti-TNFalpha agent or respectively with anti-α4β7 agent. In a specific embodiment the method is suitable to assess whether such patient would be non- responsive to treatment with such anti-TNFalpha agent or respectively with anti-α4β7 agent and comprising determining a molecular signature in a biological sample previously obtained from said human patient.

Resumen de: US2019032140A1

The present invention provides a method of assessing whether an individual is at high risk or low risk of inflammatory bowel disease (IBD) progression by determining the expression level of two or more genes in a whole blood sample. Also provided are methods for treating IBD in an individual who is determined to be at high risk or low risk for IBD progression, and kits for assessing whether an individual is at high risk or low risk for IBD progression. Arrays, and methods of providing arrays, of patient-identified selected gene expression products from a whole blood sample of a patient are also provided.

Resumen de: AU2018253466A1

The present disclosure relates to methods of diagnosing a dysbiosis in a subject, methods of determining a suitable treatment, and methods of treating a dysbiosis. In some aspects, the present disclosure relates to diagnosing or determining a subtype of irritable bowel syndrome (IBS).

Resumen de: AU2014269961A1

The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, the present invention is useful for determining whether the individual does not have either celiac disease or inflammatory bowel disease (IBD), and has IBS and/or a subtype thereof. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions.

Resumen de: WO2019018571A1

Among the various aspects of the present disclosure is the provision of methods of diagnosing and treating inflammatory bowel disease (IBD) including ulcerative colitis (UC) or Crohn's disease (CD). In particular, the present disclosure provides in part a panel of IBD biomarkers useful in diagnosing and making treatment decisions. In addition, the present disclosure provides methods of treating IBD with a plasminogen activator inhibitor-1(PAI-1) inhibitor or tissue plasminogen activator (tPA).

Resumen de: WO2019016719A1

The invention relates to the use of Rho GDP dissociation inhibitory 2 protein as a diagnostic and prognostic marker of inflammatory bowel diseases by means of the ex vivo detection of the protein level in faecal samples of patients.

Resumen de: WO2019016753A1

The invention relates to the use of human Gelsolin as a diagnostic and prognostic marker of inflammatory bowel diseases by ex vivo detection of the protein level in faecal samples.

Resumen de: US2019021648A1

An apparatus and method are provided for use in studying a patient's bowel which combines recording and analysis of physiologic parameters and patient sensory perception. A pain input detector, a pain transducer, and a processor are provided. A gas pressure transducer and flow meter may also be provided. Output data may be generated to reflect perceived patient pain, volume of gas delivered to the patient's bowel, and bowel pressure. An indication of perceived patient pain is processed by the processor to generate data that may used to validate a scan of a patient or may be used as a diagnostic tool.

Resumen de: WO2019018729A1

The present invention relates to compositions and methods for identifying and treating metastatic small bowel neuroendocrine tumors.

Resumen de: WO2019018440A1

The present invention provides for a human cell atlas of the colon from healthy and diseased subjects. The atlas was obtained by single sequencing of about 117,000 cells. The present invention discloses novel markers for cell types. Moreover, genes associated with disease are identified in the colon and colon specific cell types. The invention provides for diagnostic assays based on gene markers and cell composition, as well as target cell types that express genes associated with disease. Finally, disclosed are novel cell types and methods of quantitating, detecting and isolating the cell types.

Resumen de: WO2019015814A1

The invention relates to an in vitro method for diagnosis, prognosis, risk assessment, monitoring, therapy guidance and/or therapy control of an autoimmune disorder of the digestive system, such as inflammatory bowel disease and autoimmune liver disease, in which autoantibodies that bind Chitinase-3-Like Protein 1 (CHI3L1) protein are detected as a marker of such disease. The invention therefore relate to the use of CHI3L1 as an autoantigen in autoimmune diagnostics if diseases of the digestive system. A kit and system for conducting the method are encompassed by the invention.

Resumen de: WO2019014714A1

The present disclosure relates to methods of diagnosing a dysbiosis in a subject, methods of determining a suitable treatment, and methods of treating a dysbiosis. In some aspects, the present disclosure relates to diagnosing or determining a subtype of irritable bowel syndrome (IBS).